Gastric Inhibitory Polypeptide: the neglected incretin revisited

After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called “incretin effect” is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). In contrast to GLP-1, GIP h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Regulatory Peptides 2002-07, Vol.107 (1), p.1-13
Hauptverfasser: Meier, Juris J, Nauck, Michael A, Schmidt, Wolfgang E, Gallwitz, Baptist
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 13
container_issue 1
container_start_page 1
container_title Regulatory Peptides
container_volume 107
creator Meier, Juris J
Nauck, Michael A
Schmidt, Wolfgang E
Gallwitz, Baptist
description After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called “incretin effect” is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). In contrast to GLP-1, GIP has lost most of its insulinotropic effect in type 2 diabetic patients. In addition to its main physiological role in the regulation of endocrine pancreatic secretion, GIP exerts various peripheral effects on adipose tissue and lipid metabolism, thereby leading to increased lipid deposition in the postprandial state. In some animal models, an influence on gastrointestinal functions has been described. However, such effects do not seem to play an important role in humans. During the last years, the major line of research has focussed on GLP-1, due to its promising potential for the treatment of type 2 diabetes mellitus. However, the physiological importance of GIP in the regulation of insulin secretion has been shown to even exceed that of GLP-1. Furthermore, work from various groups has provided evidence that GIP contributes to the pathogenesis of type 2 diabetes to a considerable degree. Recent data with modified GIP analogues further suggested a possibility of therapeutic use in the treatment of type 2 diabetes. Thus, it seems worthwhile to refocus on this important and—sometimes—neglected incretin hormone. The present work aims to review the physiological functions of GIP, to characterize its role in the pathogenesis of type 2 diabetes, and to discuss possible clinical applications and future perspectives in the light of new findings.
doi_str_mv 10.1016/S0167-0115(02)00039-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71947923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167011502000393</els_id><sourcerecordid>71947923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-6237ad2796fb1abac820ec0edd76e5827dd60ccf30e88191550534250eefa0643</originalsourceid><addsrcrecordid>eNqFkN9LwzAQx4Mobv74E5S-KPpQvSRN0_qiMnQOBgrqc8iSq4t07Uy6wf57u624R1_u4Ph8744PIWcUbijQ9Pa9LTIGSsUVsGsA4HnM90ifZpLHNM3SfdL_Q3rkKIRvACqk5IekRxnlMk-hTx6GOjTemWhUTd3ENbVfRW91uZrjvHEW76JmilGFXyWaBm3kKuOxcVXkcemCa0cn5KDQZcDTrh-Tz-enj8FLPH4djgaP49gkQjZxyrjUlrVHiwnVE20yBmgArZUpioxJa1MwpuCAWUZzKgQInjABiIWGNOHH5HK7d-7rnwWGRs1cMFiWusJ6EZSkeSJzxltQbEHj6xA8Fmru3Uz7laKg1urURp1ae1HA1EadWufOuwOLyQztLtW5aoGLDtDB6LLwujIu7DiesUQmWcvdbzlsdSwdehWMw8qgdb61qGzt_nnlFz7eil0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71947923</pqid></control><display><type>article</type><title>Gastric Inhibitory Polypeptide: the neglected incretin revisited</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Meier, Juris J ; Nauck, Michael A ; Schmidt, Wolfgang E ; Gallwitz, Baptist</creator><creatorcontrib>Meier, Juris J ; Nauck, Michael A ; Schmidt, Wolfgang E ; Gallwitz, Baptist</creatorcontrib><description>After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called “incretin effect” is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). In contrast to GLP-1, GIP has lost most of its insulinotropic effect in type 2 diabetic patients. In addition to its main physiological role in the regulation of endocrine pancreatic secretion, GIP exerts various peripheral effects on adipose tissue and lipid metabolism, thereby leading to increased lipid deposition in the postprandial state. In some animal models, an influence on gastrointestinal functions has been described. However, such effects do not seem to play an important role in humans. During the last years, the major line of research has focussed on GLP-1, due to its promising potential for the treatment of type 2 diabetes mellitus. However, the physiological importance of GIP in the regulation of insulin secretion has been shown to even exceed that of GLP-1. Furthermore, work from various groups has provided evidence that GIP contributes to the pathogenesis of type 2 diabetes to a considerable degree. Recent data with modified GIP analogues further suggested a possibility of therapeutic use in the treatment of type 2 diabetes. Thus, it seems worthwhile to refocus on this important and—sometimes—neglected incretin hormone. The present work aims to review the physiological functions of GIP, to characterize its role in the pathogenesis of type 2 diabetes, and to discuss possible clinical applications and future perspectives in the light of new findings.</description><identifier>ISSN: 0167-0115</identifier><identifier>EISSN: 1873-1686</identifier><identifier>DOI: 10.1016/S0167-0115(02)00039-3</identifier><identifier>PMID: 12137960</identifier><identifier>CODEN: REPPDY</identifier><language>eng</language><publisher>Shannon: Elsevier B.V</publisher><subject>Adipose Tissue - drug effects ; Adipose Tissue - physiology ; Amino Acid Sequence ; Animals ; Biological and medical sciences ; Blood Glucose - analysis ; C-Peptide - blood ; Diabetes Mellitus, Type 2 - pathology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Gastric Inhibitory Polypeptide - metabolism ; Gastric Inhibitory Polypeptide - pharmacology ; Gastric Inhibitory Polypeptide - physiology ; Glucagon - metabolism ; Glucagon-Like Peptide 1 ; Glucose - metabolism ; Humans ; Incretin effect ; Insulin - blood ; Insulin secretion ; Lipids - physiology ; Medical sciences ; Models, Biological ; Molecular Sequence Data ; Pancreatic Hormones - metabolism ; Pathogenesis of type 2 diabetes ; Peptide Fragments - metabolism ; Postprandial Period ; Protein Precursors - metabolism ; Secretin - pharmacology ; Sequence Homology, Amino Acid ; Stomach - drug effects ; Stomach - physiology ; Treatment of type 2 diabetes</subject><ispartof>Regulatory Peptides, 2002-07, Vol.107 (1), p.1-13</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-6237ad2796fb1abac820ec0edd76e5827dd60ccf30e88191550534250eefa0643</citedby><cites>FETCH-LOGICAL-c457t-6237ad2796fb1abac820ec0edd76e5827dd60ccf30e88191550534250eefa0643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167011502000393$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,776,780,788,3537,27899,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13824748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12137960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meier, Juris J</creatorcontrib><creatorcontrib>Nauck, Michael A</creatorcontrib><creatorcontrib>Schmidt, Wolfgang E</creatorcontrib><creatorcontrib>Gallwitz, Baptist</creatorcontrib><title>Gastric Inhibitory Polypeptide: the neglected incretin revisited</title><title>Regulatory Peptides</title><addtitle>Regul Pept</addtitle><description>After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called “incretin effect” is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). In contrast to GLP-1, GIP has lost most of its insulinotropic effect in type 2 diabetic patients. In addition to its main physiological role in the regulation of endocrine pancreatic secretion, GIP exerts various peripheral effects on adipose tissue and lipid metabolism, thereby leading to increased lipid deposition in the postprandial state. In some animal models, an influence on gastrointestinal functions has been described. However, such effects do not seem to play an important role in humans. During the last years, the major line of research has focussed on GLP-1, due to its promising potential for the treatment of type 2 diabetes mellitus. However, the physiological importance of GIP in the regulation of insulin secretion has been shown to even exceed that of GLP-1. Furthermore, work from various groups has provided evidence that GIP contributes to the pathogenesis of type 2 diabetes to a considerable degree. Recent data with modified GIP analogues further suggested a possibility of therapeutic use in the treatment of type 2 diabetes. Thus, it seems worthwhile to refocus on this important and—sometimes—neglected incretin hormone. The present work aims to review the physiological functions of GIP, to characterize its role in the pathogenesis of type 2 diabetes, and to discuss possible clinical applications and future perspectives in the light of new findings.</description><subject>Adipose Tissue - drug effects</subject><subject>Adipose Tissue - physiology</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - analysis</subject><subject>C-Peptide - blood</subject><subject>Diabetes Mellitus, Type 2 - pathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Gastric Inhibitory Polypeptide - metabolism</subject><subject>Gastric Inhibitory Polypeptide - pharmacology</subject><subject>Gastric Inhibitory Polypeptide - physiology</subject><subject>Glucagon - metabolism</subject><subject>Glucagon-Like Peptide 1</subject><subject>Glucose - metabolism</subject><subject>Humans</subject><subject>Incretin effect</subject><subject>Insulin - blood</subject><subject>Insulin secretion</subject><subject>Lipids - physiology</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Molecular Sequence Data</subject><subject>Pancreatic Hormones - metabolism</subject><subject>Pathogenesis of type 2 diabetes</subject><subject>Peptide Fragments - metabolism</subject><subject>Postprandial Period</subject><subject>Protein Precursors - metabolism</subject><subject>Secretin - pharmacology</subject><subject>Sequence Homology, Amino Acid</subject><subject>Stomach - drug effects</subject><subject>Stomach - physiology</subject><subject>Treatment of type 2 diabetes</subject><issn>0167-0115</issn><issn>1873-1686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkN9LwzAQx4Mobv74E5S-KPpQvSRN0_qiMnQOBgrqc8iSq4t07Uy6wf57u624R1_u4Ph8744PIWcUbijQ9Pa9LTIGSsUVsGsA4HnM90ifZpLHNM3SfdL_Q3rkKIRvACqk5IekRxnlMk-hTx6GOjTemWhUTd3ENbVfRW91uZrjvHEW76JmilGFXyWaBm3kKuOxcVXkcemCa0cn5KDQZcDTrh-Tz-enj8FLPH4djgaP49gkQjZxyrjUlrVHiwnVE20yBmgArZUpioxJa1MwpuCAWUZzKgQInjABiIWGNOHH5HK7d-7rnwWGRs1cMFiWusJ6EZSkeSJzxltQbEHj6xA8Fmru3Uz7laKg1urURp1ae1HA1EadWufOuwOLyQztLtW5aoGLDtDB6LLwujIu7DiesUQmWcvdbzlsdSwdehWMw8qgdb61qGzt_nnlFz7eil0</recordid><startdate>20020715</startdate><enddate>20020715</enddate><creator>Meier, Juris J</creator><creator>Nauck, Michael A</creator><creator>Schmidt, Wolfgang E</creator><creator>Gallwitz, Baptist</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020715</creationdate><title>Gastric Inhibitory Polypeptide: the neglected incretin revisited</title><author>Meier, Juris J ; Nauck, Michael A ; Schmidt, Wolfgang E ; Gallwitz, Baptist</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-6237ad2796fb1abac820ec0edd76e5827dd60ccf30e88191550534250eefa0643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adipose Tissue - drug effects</topic><topic>Adipose Tissue - physiology</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - analysis</topic><topic>C-Peptide - blood</topic><topic>Diabetes Mellitus, Type 2 - pathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Gastric Inhibitory Polypeptide - metabolism</topic><topic>Gastric Inhibitory Polypeptide - pharmacology</topic><topic>Gastric Inhibitory Polypeptide - physiology</topic><topic>Glucagon - metabolism</topic><topic>Glucagon-Like Peptide 1</topic><topic>Glucose - metabolism</topic><topic>Humans</topic><topic>Incretin effect</topic><topic>Insulin - blood</topic><topic>Insulin secretion</topic><topic>Lipids - physiology</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Molecular Sequence Data</topic><topic>Pancreatic Hormones - metabolism</topic><topic>Pathogenesis of type 2 diabetes</topic><topic>Peptide Fragments - metabolism</topic><topic>Postprandial Period</topic><topic>Protein Precursors - metabolism</topic><topic>Secretin - pharmacology</topic><topic>Sequence Homology, Amino Acid</topic><topic>Stomach - drug effects</topic><topic>Stomach - physiology</topic><topic>Treatment of type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meier, Juris J</creatorcontrib><creatorcontrib>Nauck, Michael A</creatorcontrib><creatorcontrib>Schmidt, Wolfgang E</creatorcontrib><creatorcontrib>Gallwitz, Baptist</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Regulatory Peptides</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meier, Juris J</au><au>Nauck, Michael A</au><au>Schmidt, Wolfgang E</au><au>Gallwitz, Baptist</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric Inhibitory Polypeptide: the neglected incretin revisited</atitle><jtitle>Regulatory Peptides</jtitle><addtitle>Regul Pept</addtitle><date>2002-07-15</date><risdate>2002</risdate><volume>107</volume><issue>1</issue><spage>1</spage><epage>13</epage><pages>1-13</pages><issn>0167-0115</issn><eissn>1873-1686</eissn><coden>REPPDY</coden><abstract>After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called “incretin effect” is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). In contrast to GLP-1, GIP has lost most of its insulinotropic effect in type 2 diabetic patients. In addition to its main physiological role in the regulation of endocrine pancreatic secretion, GIP exerts various peripheral effects on adipose tissue and lipid metabolism, thereby leading to increased lipid deposition in the postprandial state. In some animal models, an influence on gastrointestinal functions has been described. However, such effects do not seem to play an important role in humans. During the last years, the major line of research has focussed on GLP-1, due to its promising potential for the treatment of type 2 diabetes mellitus. However, the physiological importance of GIP in the regulation of insulin secretion has been shown to even exceed that of GLP-1. Furthermore, work from various groups has provided evidence that GIP contributes to the pathogenesis of type 2 diabetes to a considerable degree. Recent data with modified GIP analogues further suggested a possibility of therapeutic use in the treatment of type 2 diabetes. Thus, it seems worthwhile to refocus on this important and—sometimes—neglected incretin hormone. The present work aims to review the physiological functions of GIP, to characterize its role in the pathogenesis of type 2 diabetes, and to discuss possible clinical applications and future perspectives in the light of new findings.</abstract><cop>Shannon</cop><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>12137960</pmid><doi>10.1016/S0167-0115(02)00039-3</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-0115
ispartof Regulatory Peptides, 2002-07, Vol.107 (1), p.1-13
issn 0167-0115
1873-1686
language eng
recordid cdi_proquest_miscellaneous_71947923
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adipose Tissue - drug effects
Adipose Tissue - physiology
Amino Acid Sequence
Animals
Biological and medical sciences
Blood Glucose - analysis
C-Peptide - blood
Diabetes Mellitus, Type 2 - pathology
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Gastric Inhibitory Polypeptide - metabolism
Gastric Inhibitory Polypeptide - pharmacology
Gastric Inhibitory Polypeptide - physiology
Glucagon - metabolism
Glucagon-Like Peptide 1
Glucose - metabolism
Humans
Incretin effect
Insulin - blood
Insulin secretion
Lipids - physiology
Medical sciences
Models, Biological
Molecular Sequence Data
Pancreatic Hormones - metabolism
Pathogenesis of type 2 diabetes
Peptide Fragments - metabolism
Postprandial Period
Protein Precursors - metabolism
Secretin - pharmacology
Sequence Homology, Amino Acid
Stomach - drug effects
Stomach - physiology
Treatment of type 2 diabetes
title Gastric Inhibitory Polypeptide: the neglected incretin revisited
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T21%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20Inhibitory%20Polypeptide:%20the%20neglected%20incretin%20revisited&rft.jtitle=Regulatory%20Peptides&rft.au=Meier,%20Juris%20J&rft.date=2002-07-15&rft.volume=107&rft.issue=1&rft.spage=1&rft.epage=13&rft.pages=1-13&rft.issn=0167-0115&rft.eissn=1873-1686&rft.coden=REPPDY&rft_id=info:doi/10.1016/S0167-0115(02)00039-3&rft_dat=%3Cproquest_cross%3E71947923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71947923&rft_id=info:pmid/12137960&rft_els_id=S0167011502000393&rfr_iscdi=true